louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06516640: Type 2 Continuous Glucose Monitoring Academy
Official title: Randomized Control Trial Evaluating the Impact of Continuous Glucose Monitoring Academy Education Curriculum Versus Standard Care on Glycemic Outcomes for Youth With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Type 2 Diabetes
Keywords: Continuous Glucose Monitoring
Glycemic Control
Diabetes Education
Type 2 Diabetes
Lead sponsor: Children's Hospital Los Angeles
Sponsor class: OTHER
Collaborators: name: National Institute on Minority Health and Health Disparities (NIMHD)
First posted: 2024-07-24
Enrollment: 60
Sex: ALL
Minimum age (years): 13
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to evaluate the Impact of Continuous Glucose Monitoring Academy Education Curriculum Versus Standard Care on Glycemic Outcomes for Youth With Type 2 Diabetes (T2D):

* The first aim is to determine how feasible it is to adapt the Continuous Glucose Monitoring Academy curriculum to teach youth with T2D glucose management strategies.
* The second aim is to evaluate the effects of the Continuous Glucose Monitoring Academy metrics.
* The third aim is to explore the relationships between these metrics with diabetes distress, diabetes family responsibilities, and process metrics.

Participants will join for a total of four weeks of education, followed by a six-month clinical review. They will have access to an online workbook and videos, and will participate in virtual sessions with a diabetes educator who will cover glucose management strategies in-depth. Participants will wear their preferred Continuous Glucose Monitoring system (Dexcom or FreeStyle Libre) provided via insurance and inserted at the baseline visit.


Eligibility criteria: Inclusion Criteria:

1. Current age of 13-24 years;
2. T2D diagnosis;
3. Able to speak, read, and write English or Spanish

Exclusion Criteria:

a. Known history of medical adhesive allergies;

Primary outcomes:
measure: Mean change in Time in Range (TIR) from baseline to 6 months
timeFrame: Baseline to 6 months
Secondary outcomes:
measure: Mean change in Hemoglobin A1c (HbA1c) from baseline to 6 months
timeFrame: Baseline to 6 months
measure: Mean change in CGM metrics measured by CGM readings
timeFrame: Week 4 & 6 months
measure: Change in perceived diabetes distress at baseline, week 4 & 6 months
timeFrame: Baseline, Week 4 & 6 months
measure: Change in perceived diabetes family responsibility at baseline, week 4 & 6 months
timeFrame: Baseline, week 4 & 6 months
measure: Average number of diabetes educator hours used per study participant at week 4 & 6 months.
timeFrame: Week 4 and 6 months
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Children's Hospital Los Angeles
state: California
Study officials:
affiliation: Children's Hospital Los Angeles
name: Rebecca Barber, PhD, RN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04675840: Intrathecal Morphine for Robotic-assisted Laparoscopic Hysterectomy.
Official title: Intrathecal Morphine for Robotic-assisted Laparoscopic Hysterectomy- a Prospective Randomized Controlled Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Opioid-Related Disorders
Lead sponsor: Karlstad Central Hospital
Sponsor class: OTHER
First posted: 2020-12-19
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Is there any difference in the intensity of postoperative pain, nausea, urinary retention and legth of hospital stay in patients undergoing robotic assisted laparoscopic surgery if they receive intrathecal morphine or peroral and intravenous opiates during the surgery and is there a significant difference in the need of opiates after the surgery.


Eligibility criteria: Inclusion Criteria:

\* Patients accepted for robotic-assisted laparoscopic surgery

Exclusion Criteria:

* Coagulopathy,
* Prior spine surgery,
* Chronic pain problems,
* Drug abuse,
* Pregnancy
* \< 18 years

Primary outcomes:
measure: Postop morphine consumption
timeFrame: First 48 hours after surgery
measure: Postop grade of nausea & vomiting
timeFrame: First 24 hours after surgery
Secondary outcomes:
measure: Hospital length of stay.
timeFrame: Up to 7 days
measure: Patient overall satisfaction score.
timeFrame: Up to 7 days.
Other outcomes:
Locations:
city: Karlstad
country: Sweden
facility: Department of Anesthesia & Intensive Care
state: Värmland
Study officials:
affiliation: Dpt of Anesthesiology & Intensive Care
name: Ragnar N Henningsson, Associate Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00331240: 24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination
Official title: 24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Primary Open Angle Glaucoma
Exfoliation Syndrome
Lead sponsor: Aristotle University Of Thessaloniki
Sponsor class: OTHER
First posted: 2006-05-29
Enrollment: 32
Sex: ALL
Minimum age (years): 29
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the short-term (8 week) mean 24-hour intraocular pressure control and safety of TravTim fixed combination given once in the evening with placebo once in the morning versus TravTim given once in the morning with placebo once in the evening in patients with open-angle glaucoma.


Eligibility criteria: Inclusion Criteria:

* POAG
* Exfoliation syndrome

Exclusion Criteria:

* Advanced glaucoma

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Thessaloniki
country: Greece
facility: Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital
Study officials:
affiliation: Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital
name: AGP Konstas, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02464540: Optical Properties of Light Cured Luting Agent on Laminate Veneer
Official title: Randomized Clinical Trial of Light Cured Luting Agents on Laminate Veneers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Optical Properties of Laminate Veneers
Keywords: laminate veneers
luting agent
Lead sponsor: Federal University of Pelotas
Sponsor class: OTHER
First posted: 2015-06-08
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this randomized clinical trial is to evaluate the influence of luting agent, thickness and color of laminate veneers (LVs) and color of dental substrate on the optical properties of LVs.

Detailed description: The following date will be collected (i) the color of dental substrate obtained before and after dental preparation, (ii) the thickness and color of the LVs obtained before of the cementation procedures on white and black value background, (iii) and the final color of the LVs bonded to dental substrates obtained after cementation. For LVs cementation two cements will be used, the light-cured resin cement and the flowable composite, which will be randomly divided into two groups (n=31). The color of LVs will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL\*a\* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.

Eligibility criteria: Inclusion Criteria:

* Minimum 18 years of age
* Patients with diastema
* Conoid teeth
* Misaligned anterior teeth
* Discolored teeth and/or teeth with erosion/abrasion
* Posterior occlusal stability
* Individuals who are willing to attend the clinics on predetermined days, to agree to sign the consent form and clarified, after receiving information about the study objectives, risks and benefits associated with the procedures.

Exclusion Criteria:

* Patients with extensive loss of tooth structure
* Subjects suffering from temporomandibular disorders, neurological and oral mucosa diseases
* Inadequate oral hygiene or periodontal problems
* Smokers

Primary outcomes:
measure: Optical Properties of Laminate Veneers
timeFrame: after luting the laminate veneers (at least 1 hours after cementation)
Secondary outcomes:
Other outcomes:
Locations:
city: Pelotas
country: Brazil
facility: Noéli Boscato
state: RS
Study officials:
affiliation: Federal University of Pelotas
name: Noéli Boscato, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04783740: Validity and Reliability of Turkish Version of The Working Memory Questionnaire
Official title: Validity and Reliability of Turkish Version of The Working Memory Questionnaire
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Working Memory
The Working Memory Questionnaire
Lead sponsor: Kutahya Health Sciences University
Sponsor class: OTHER
First posted: 2021-03-05
Enrollment: 303
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Individuals living in Turkey

Brief summary: The aim of this study was to determine the Turkish validity and reliability of ''The Working Memory Questionnaire'' developed by Dr. Vallat-Azouvi.

Detailed description: Working Memory refers to the temporary storage and exchange of information required for complex tasks such as language, understanding, learning, and reasoning. Working memory deficits are worse in people with advanced age and low education. In addition, working memory is impaired in children with traumatic brain injury, stroke, Alzheimer's disease, and attention deficit hyperactivity disorder. The aim of this study is to determine the Turkish version, validity, and reliability of ''The Working Memory Questionnaire''. 300 health people will include in the study. In order to determine the reliability of the scale, the intraclass correlation coefficient (ICC) will be used to determine the level of the relationship between the results of the first and second measurements. Cronbach's alpha coefficient will be used for the homogeneity of the questions in the scale. For construct validity, the correlation coefficient will be used to determine the agreement between the Turkish Version of Cognitive Failures Questionnaire and The Working Memory Questionnaire.

Eligibility criteria: Inclusion Criteria:

* Being an individual between the ages of 18-50

Exclusion Criteria:

* Having a neurological and mental illness

Primary outcomes:
measure: The Working Memory Questionnaire
timeFrame: 15 minute
Secondary outcomes:
measure: Turkish Version Cognitive Failures Questionnaire
timeFrame: 12 minute
Other outcomes:
Locations:
city: Kütahya
country: Turkey
facility: Kutahya Health Sciences University
state: Merkez
Study officials:
affiliation: Kutahya Health Sciences University
name: Cihan Caner AKSOY, PhD
role: STUDY_DIRECTOR
affiliation: Kutahya Health Sciences University
name: İsmail SARAÇOĞLU, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Kutahya Health Sciences University
name: Lütfiye AKKURT, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04311840: Impact of Nimodipine on Sublingual Microcirculation in Patients With Hemorrhage - a Prospective Monocentric Observational Study
Official title: Impact of Nimodipine on Sublingual Microcirculation in Patients With Subarachnoid Hemorrhage - a Prospective Monocentric Observational Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Subarachnoid Hemorrhage
Keywords: nimodipine
sublingual microcirculation
Side-stream Dark Field imaging
Lead sponsor: University Hospital Hradec Kralove
Sponsor class: OTHER
First posted: 2020-03-17
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adult patients admitted to the neurosurgical ICU with the diagnosis of subarachnoid hemorrhage. Might be alert, somnolent or sedated on mechanical ventilation. Might be after endovascular coiling or surgical clipping of the aneurysm.

Brief summary: Nimodipine can increase Functional Capillary Density (FCD) as a parameter of the sublingual microcirculation in patients with subarachnoid hemorrhage (SAH) compared to patients without nimodipine.

Detailed description: SAH group - in patients with SAH and documented vasospasms by digital subtraction angiography (DSA) of trans-cranial doppler imaging (TCD) of arteria cerebri media nimodipine is indicated because it is proven to improve the clinical outcome. The disfunction of cerebral microcirculation in rats with SAH has been documented \[1-6\]. Changes in sublingual microcirculation in patients with SAH with documented vasospasms with nimodipine has not been described.

Eligibility criteria: Inclusion Criteria:

* adulthood
* ICU admission
* diagnosis of non-traumatic subarachnoid hemorrhage

Exclusion Criteria:

* inherited coagulation disorder
* rheumatic disease
* microangiopathy
* patient of representative refusal

Primary outcomes:
measure: Functional capillary density (FCD)
timeFrame: One week
measure: Proportion of perfused vessels (PPV)
timeFrame: One week
Secondary outcomes:
measure: Vasospasm occurence
timeFrame: One week
measure: Circulatory incoherence
timeFrame: One week
Other outcomes:
Locations:
city: Hradec Králové
country: Czechia
facility: University Hospital Hradec Kralove
state: Třebeš
Study officials:
References:
Clinical trial NCT06013540: Comparison Of Efficacy Of Combination Of TAM Formula Vs Kligman Formula For Melasma.
Official title: Comparison Of The Efficacy Of Combination Of TAM Formula Versus Kligman Formula For Melasma At Tertiary Care Hospital,Karachi.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Melasma
Lead sponsor: Jinnah Postgraduate Medical Centre
Sponsor class: OTHER_GOV
First posted: 2023-08-28
Enrollment: 122
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study would offer the participants about the knowledge of these formula in the treatment of melasma and help the investigators in incorporating and updating the management protocols in medical practice.


Eligibility criteria: Inclusion Criteria:

* Patients between 25-65 years of age, either gender having melasma for over one month will be included in the study
* Exclusion Criteria:

  * Pregnancy, breastfeeding, taking birth control pills or plans to become pregnant during the study
  * History of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis
  * History of skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy
  * History of uncorrected coagulation defect or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy)
  * History of sensitivity to hydroquinone or Retin-A
  * History of evidence of a compromised immune system or hepatitis

Primary outcomes:
measure: EFFICACY OF COMBINATION OF TAM FORMULA VERSUS KLIGMAN FORMULA IN TREATMENT OF MELASMA
timeFrame: Efficacy will be assesed upto 2 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: JPMC
state: Sindh
Study officials:
References:
Clinical trial NCT01247740: Comparison of Three-chamber-bag Versus Compounded Bag
Official title: A Prospective, Controlled, Randomized, Blinded, Parallel Group Multicentre Study on the Safety and Efficacy of a Convenience Three-chamber Bag for Parenteral Nutrition in Post-operative Patients After Abdominal Surgery Versus a Compounded Monobag
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Parenteral Nutrition for Patients With Proven Insufficient Enteral Resorption
Lead sponsor: B. Braun Melsungen AG
Sponsor class: INDUSTRY
First posted: 2010-11-24
Enrollment: 240
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to investigate the efficacy and safety of a convenient 3-chamber-bag containing aminoacids, glucose and lipid emulsion (LCT/MCT 20%) compared to a conventionally compounded monobag for parenteral nutrition.


Eligibility criteria: Inclusion: •Patients considered for elective open abdominal surgery

* Male and female patients ≥18 and \<85 years of age
* Indication for total parenteral nutrition therapy: for 6 consecutive days
* NRS ≥3
* Ability and willingness to give voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the Institutional Review Board (IRB) prior to all evaluations, and to comply with the requirements of the study

Exclusion: Major criteria:

* Body weight \< 50 kg or \> 70 kg
* Laparoscopic surgery
* Seriously ill patients in need of high energy nutrition support (i. e. \> 2100 Kcal/day)
* Hepatic surgery
* Surgery with estimated blood loss \>1000ml
* Participation in a clinical study with an investigational drug or an investigational medical device within one month prior to the start of study
* Receiving regular parenteral nutrition within 7 days before the onset of study
* General contraindications for parenteral nutrition (acidosis of various geneses, untreated disorders of electrolyte and fluid balance, hyperhydration, acute pulmonary edema, inadequate cellular oxygen supply)
* General contraindications for infusion therapy such as acute pulmonary oedema, hyperhydration and decompensated cardiac insufficiency, acute stroke
* Known hypersensitivity to egg-, soy-, and peanut proteins or any of the ingredients

Primary outcomes:
measure: Course of prealbumin (from day 1 to day 7)
timeFrame: 7 days
Secondary outcomes:
measure: clinical outcome parameters, haematology, liver function, blood biochemistry and electrolytes, coagulation function
timeFrame: 7 days
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital,Department of Gastrointestinal Surgery
Study officials:
affiliation: Peking Union Medical College Hospital,Department of Gastrointestinal Surgery
name: Jianchun Yu, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00398840: A Study of ARQ 171 in Patients With Advanced Solid Tumors
Official title: A Phase 1 Dose Escalation Study of ARQ 171 in Adult Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Cancer
Keywords: Cancer
Solid Tumors
advanced solid tumors
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Sponsor class: INDUSTRY
First posted: 2006-11-14
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open label, dose escalation study of ARQ 171 administered via intravenous infusion (IVI) into a peripheral vein weekly.

Patients with advanced solid tumors, who are refractory to available therapy or for whom no standard systemic therapy exists, will be enrolled.


Eligibility criteria: Inclusion Criteria:

* Signed written informed consent must be obtained and documented prior to study-specific screening procedures.
* A histologically or cytologically confirmed advanced solid tumor
* ≥ 18 years of age
* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors
* Karnofsky performance status ≥ 70%
* Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after participation.
* Females of childbearing potential must have a negative serum pregnancy test.
* Laboratory results must meet study criteria.

Exclusion Criteria:

* Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of first infusion
* Surgery within 4 weeks prior to first infusion
* Known untreated brain metastases
* Pregnant or breastfeeding
* Uncontrolled intercurrent illness, or uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
* Other cancer within the last five years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin

Primary outcomes:
measure: To determine the safety, tolerability and maximum tolerated dose (MTD) of ARQ 171
Secondary outcomes:
measure: To determine the pharmacokinetic profile of ARQ 171
measure: To assess the preliminary anti-tumor activity of ARQ 171
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: Premiere Oncology
state: California
city: Boston
country: United States
facility: Dana Farber/Harvard Cancer Center
state: Massachusetts
city: Dallas
country: United States
facility: Mary Crowley Medical Research Center
state: Texas
Study officials:
References: